KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Assets: 2011-2025

Historic Assets for Sarepta Therapeutics (SRPT) over the last 14 years, with Sep 2025 value amounting to $3.5 billion.

  • Sarepta Therapeutics' Assets fell 2.96% to $3.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 billion, marking a year-over-year decrease of 2.96%. This contributed to the annual value of $4.0 billion for FY2024, which is 21.40% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Assets stood at $3.5 billion for Q3 2025, which was down 5.06% from $3.7 billion recorded in Q2 2025.
  • Over the past 5 years, Sarepta Therapeutics' Assets peaked at $4.0 billion during Q4 2024, and registered a low of $2.7 billion during Q3 2021.
  • Over the past 3 years, Sarepta Therapeutics' median Assets value was $3.4 billion (recorded in 2024), while the average stood at $3.4 billion.
  • Per our database at Business Quant, Sarepta Therapeutics' Assets fell by 6.18% in 2021 and then increased by 21.40% in 2024.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Assets stood at $3.1 billion in 2021, then declined by 0.62% to $3.1 billion in 2022, then climbed by 4.35% to $3.3 billion in 2023, then rose by 21.40% to $4.0 billion in 2024, then fell by 2.96% to $3.5 billion in 2025.
  • Its last three reported values are $3.5 billion in Q3 2025, $3.7 billion for Q2 2025, and $3.5 billion during Q1 2025.